KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment

Fluoropyrimidine-based chemotherapy plus antibody therapy is currently the standard first-line treatment for metastatic colorectal cancer (mCRC). In this study, we investigated the hypothesis that mutations in several of the targeted oncogenes are correlated with treatment outcomes in mCRC patients...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: SOEDA, HIROSHI, SHIMODAIRA, HIDEKI, WATANABE, MIKA, SUZUKI, TAKAO, GAMO, MAKIO, TAKAHASHI, MASANOBU, KOMINE, KEIGO, KATO, SHUNSUKE, ISHIOKA, CHIKASHI
Format: Artigo
Langue:Inglês
Publié: D.A. Spandidos 2014
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3999142/
https://ncbi.nlm.nih.gov/pubmed/24772300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.254
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires